Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KIORA PHARMACEUTICALS INCKPRX · Entity 7940 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KIORA PHARMACEUTICALS INC
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.63 · Expires 2036-06-10 | Direct | 25,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 25,000 · Balance 25,000 F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALIMERA SCIENCES INC
Report date September 16, 2024 · Filed September 18, 2024
Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.99 · Expires 2033-10-01 | Direct | 0 |
Reported balance
After 2024-09-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-16 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.72 · Expires 2033-01-03 | Direct | 0 |
Reported balance
After 2024-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-09-16 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.23 · Expires 2031-11-29 | Direct | 0 |
Reported balance
After 2024-09-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-09-16 · Disposition to issuer · Disposed 3,255 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to:
F2: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 16:15 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001895795-26-000001 · wk-form4_1781295350.xml · derivative · entry 1 Parsons Erin · CIK 0001895795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 20:15 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001372514-25-000029 · wk-form4_1743639351.xml · derivative · entry 1 Parsons Erin · CIK 0001895795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-04-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on April 1, 2026. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:52 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,255 | Not disclosed Strike: $5.23 | Not disclosed |
DisclosureSEC source: 0001104659-24-101108 · tm2424353-7_4seq1.xml · derivative · entry 3 Parsons Erin · CIK 0001895795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,255 shares Expires 2031-11-29 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2 · price: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2 · derivative.exercise_date: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:52 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $2.72 | Not disclosed |
DisclosureSEC source: 0001104659-24-101108 · tm2424353-7_4seq1.xml · derivative · entry 2 Parsons Erin · CIK 0001895795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2033-01-03 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2 · price: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2 · derivative.exercise_date: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:52 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $2.99 | Not disclosed |
DisclosureSEC source: 0001104659-24-101108 · tm2424353-7_4seq1.xml · derivative · entry 1 Parsons Erin · CIK 0001895795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2033-10-01 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2 · price: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2 · derivative.exercise_date: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 15:15 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 1,778 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001372514-24-000092 · wk-form4_1720034152.xml · derivative · entry 1 Parsons Erin · CIK 0001895795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,778 Underlying: Common Stock · 1,778 shares Expires 2034-07-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on July 1, 2025. Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 15:51 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | PurchaseCommon Stock | 5,260 | $4.88 | $25,668.80 |
DisclosureSEC source: 0001372514-24-000061 · wk-form4_1718308256.xml · nonDerivative · entry 1 Parsons Erin · CIK 0001895795 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 5,260 Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 16:46 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0000950170-23-051941 · ownership.xml · derivative · entry 1 Parsons Erin · CIK 0001895795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-10-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments beginning on August 1, 2023. Vests in full on the earlier of August 1, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, provided the Reporting Person provides continuous service to the Issuer through such date, with the final installment adjusted as necessary to avoid any fractional shares in any installment. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 16:43 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001372514-23-000142 · wk-form4_1696365787.xml · derivative · entry 1 Parsons Erin · CIK 0001895795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2033-09-29 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on September 29, 2024. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 20:15 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0001372514-23-000037 · wf-form4_167823812887709.xml · derivative · entry 1 Parsons Erin · CIK 0001895795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-03-03 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on March 3, 2024. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 19:26 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001474506-23-000013 · primary_doc.xml · derivative · entry 1 Parsons Erin · CIK 0001895795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: Vests in full on the date of the Issuer's annual meeting of stockholders in 2023 or any special meeting held in lieu thereof, provided the Reporting Person provides continuous service to the Issuer through such date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 19:04 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001104659-22-011494 · tm225348d6_4.xml · derivative · entry 2 Parsons Erin · CIK 0001895795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-02-01 F2 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2023. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 19:04 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001104659-22-011494 · tm225348d6_4.xml · derivative · entry 1 Parsons Erin · CIK 0001895795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan in connection with the Reporting Person's appointment to the Issuer's Board of Directors. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 13:17 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantStock Option (Right to Buy) · Derivative | 3,255 | $0.00 Strike: $5.23 | $0.00 |
DisclosureSEC source: 0001474506-21-000171 · primary_doc.xml · derivative · entry 1 Parsons Erin · CIK 0001895795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,255 Underlying: Common Stock · 3,255 shares Expires 2031-11-29 F1 · derivative.exercise_date: Becomes exercisable in equal monthly installments of 465 shares on the 15th day of each month from December 15, 2021 through June 15, 2022, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.